Catch up with the latest trial data on HLH/MAS presented at #ACR25, including biomarker-driven breakthroughs and early diagnostic strategies, free and on demand with Medthority #MedSky #MedEd #RareDisease #Hematology #Rheumatology #RheumSky ow.ly/pq7y50XsOPg

We're nearly halfway through #Movember! Head over to Medthority to get closer to the conversations that matter in men's health with our Prostate Cancer Nexus, designed to support your clinical decisions #MedSky #ProstateCancer #MensHealth #MedEd ow.ly/CWTe50XrGsC

Do you care for people with a rare disease? Navigate these complex conditions with the latest congress highlights and expert opinions on a range of diseases, from HLH/MAS to NF1 #MedSky #RareDisease #MedEd ow.ly/Oc0Q50Xrf4X

🫁 This #LungCancerAwarenessMonth, catch up with the latest trial data from #ESMO25 on non-small-cell lung cancer (NSCLC). From treatment guidance to "reassuring" trial outcomes, get the updates you need to know on Medthority #MedSky #LungCancer ow.ly/fnwp50XqsyE

With new treatment options and assessment tools emerging, make sure your #alopeciaareata (AA) patients are getting the best possible care with expert insights in our NEW podcast series, Alopecia Areata in Conversation #MedSky #DermSky ow.ly/vv1F50Xq2pE

📰 It's news-day Tuesday! High energy sound waves promote healing of diabetic foot ulcers, suggests a new study. Plus, can viral infections increase risk of heart disease and stroke?🫀 Catch up with the news you need to know on Medthority: ow.ly/MOeT50XpQkB #MedSky #MedNews #MedEd

Did you know you can watch exclusive Medthority videos on YouTube? Head over to our channel for expert perspectives on a range of specialties, from congress highlights at #ESMO25 to insights on shared decision-making in atrial fibrillation #MedSky #MedEd ow.ly/fult50Xn2wX

What does Félix Guerrero-Ramos think of upcoming shifts in clinical practice when managing #NMIBC? Guerrero-Ramos discusses what he’d like to see in future guidelines, including biomarker selection and better patient classification, at #ESMO25 #MedSky #OncSky ow.ly/pX2E50XooEi

How is the NMIBC treatment landscape shifting? Listen to Ashish Kamat host expert discussions with Roger Li, Joshua Meeks, and Fred Witjes in the latest episodes of our new podcast series, for insights that fit into your busy schedule #MedSky #BladderCancer #MedicalPodcast ow.ly/c9vI50XnW2P

Get closer to the conversations that are changing clinical practice with our key highlights from #ESMO25. From summaries of the latest trial data to expert interviews, catch up with insights on bladder, prostate, and lung cancer care #MedSky #OncSky ow.ly/Ho3q50Xnaux

Did you miss DGHO 2025? Stay up to date with insights from Bernd Kasper and Maya Niethard on desmoid tumor care, from diagnostic assessment and patient communication to management from a surgeon's perspective #MedSky #MedEd #OncSky ow.ly/bPjN50XmEca

📰 It's news-day Tuesday! New trial data suggests tiny viruses may hold the key to tackling antibiotic-resistant infections, plus experimental decoy molecules may keep some viral infections at bay. Stay informed with news on Medthority #MedSky #MedicalNews ow.ly/kfCe50XmvNj

What are the main challenges in NF1-PN care and how might the evolving treatment landscape address unmet needs? Watch expert reflections from Said Farschtschi and Dusica Babovic-Vuksanovic at #EANO2025 #MedSky #NeuroSky ow.ly/GwXw50XlTn0

How can we combat the myasthenic crisis? Listen to Tobias Ruck and Nils Erik Gilhus share their clinical experience of MG, with this compelling case study to help you identify early red flags and understand the importance of timely intervention #MedSky #NeuroSky https://ow.ly/F9Tq50XkwHb

How are HRR mutations reshaping care pathways in mPC? Tune in to the first 5 episodes of our NEW podcast series to hear insights from host Alicia Morgans and guests on advances in HRR testing and the genetic landscape of mCRPC #MedSky #OncSky #ProstateCancer ow.ly/FZLx50XkjTo

This #WorldStrokeDay, get the updates you need to know with our expert podcast series, Thrombosis in Conversation, hosted by @gbarnesmd.bsky.social. Stay ahead with highlights from #ESC2025, plus insights from Deborah Siegal on optimizing treatment duration #MedSky #CardioSky ow.ly/hh0S50XjNC4

What is Nick James’ opinion on this ‘hotly debated topic’ in #prostatecancer care discussed at #ESMO25? We spoke to James about treatment options, improving access, and the future of AI-assisted healthcare, available to watch now on Medthority #MedSky #MedEd #OncSky ow.ly/pyEs50Xj2p6

📰 It’s news-day Tuesday! Early #CIDP misdiagnosis remains common according to a recent multinational study, highlighting the need for improved diagnostic accuracy and more effective treatment strategies. Visit Medthority to find out more now #MedSky #MedEd #MedicalNews ow.ly/lVYy50XiSuw

Get the latest insights from #DGHO2025 over on our YouTube channel! Watch Bernd Kasper discuss the most significant unmet needs and the importance of understanding the lived experience of people with desmoid tumors #MedSky #OncSky ow.ly/e52g50XicbB

Heading to #ACR25 or just keeping up with the latest in #rheumatology? Check out Medthority for the opportunity to earn #CME credit with our new HLH/MAS masterclass from Fabrizio de Benedetti featuring insights on diagnosis and treatment strategies #MedSky ow.ly/sNW750XgZJo

Short on time? Catch up on advances in AATD liver care relevant to your clinical practice from #EASL2025 with our NEW visual summary. For key points on detection and care pathways, plus emerging therapies at a glance, download our infographic today #MedSky #LiverSky ow.ly/oAWW50XgYX5

Missed out on #ESMO25? Stay tuned for upcoming congress highlights that fit around your busy schedule. For now, catch up with the latest insights on improving the patient experience in #bladdercancer care from Joshua Meeks and Félix Guerrero-Ramos #MedSky #OncSky #NMIBC ow.ly/e2oz50Xgh8b

👏 That’s the end of the webinar! Thank you to our excellent speakers for their insights. The key takeaways? AA disproportionately impacts SOC populations, and more research is needed to improve patient outcomes. For now, compassion and curiosity is key 🔑 #MedSky #DermSky #InclusiveDermatology

❓ An insightful Q&A session to round-off the webinar with questions on diagnostic uncertainty, existing gaps in research in SOC populations, and how clinical trials can be more inclusive #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

💬“Communication is key and our approach is everything” - Loren Krueger. Krueger shares how to have conversations with SOC patients, including incorporating language that crosses cultures #MedSky #DermSky #InclusiveDermatology #HCPWebinar #CME #AlopeciaAreata

🔄 Loren Krueger leads the discussion on holistic AA management, addressing psychosocial impacts and inclusive hair care to support the whole patient beyond clinical symptoms #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

📂 Using real-life cases, Chair Antonella Tosti shares culturally sensitive, personalized strategies for treating AA in SOC populations, emphasizing practical, patient-centered care and the importance of trichoscopy #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

🔎 Kristen Lo Sicco highlights tools for assessing AA severity, showing how dermoscopy and structured scoring can help address disparities in diagnosis and treatment for SOC patients. Why is this important? We need to look beyond scalp hair loss! #MedSky #DermSky #HCPWebinar #CME #AlopeciaAreata

Kristen Lo Sicco shares study data on AA in SOC patients: 📈 Increased prevalence of younger patients 👩🏾 Significant female predominance ➕ Many had more than one atopic condition #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

“You have to think about how hair fits into their lives and their lifestyles.” Arash Mostaghimi urges us to approach patients with a sense of curiosity and compassion 🩷 #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

🔑 Arash Mostaghimi shares key considerations: ➿ Curly hair can hide a lot of disease ❗ Range of mimickers is much higher, especially with chronic disease #MedSky #DermSky #InclusiveDermatology #AlopeciaAreata #HCPWebinar #CME

📈 Arash Mostaghimi kicks us off with insights on the epidemiology of #alopeciaareata. The bottom line? Black and Asian patients have the highest rates of AA, but what does this mean for presentation? #MedSky #DermSky #InclusiveDermatology #HCPWebinar #CME

📣Join us for LIVE coverage of our accredited webinar ‘Inclusive approaches: Addressing #alopeciaareata in #skinofcolor populations’, starting now! Chaired by Antonella Tosti, hear from Arash Mostaghimi, Kristen Lo Sicco, and Loren Krueger on the updates you need to know #MedSky #DermSky #CME

Tune in today from 12pm EST/5pm BST for LIVE coverage of our accredited webinar, Inclusive approaches: Addressing #alopeciaareata in skin of color populations. Can’t attend? Click the link to register for the on-demand recording #MedSky #DermSky #CME ow.ly/T7ql50XfyJh

📰 It’s news-day Tuesday! Catch up with the updates you need to know from #ESMO25 with articles by our expert scientific team. From #NSCLC to #NMIBC, scroll through our news page for the latest trial data and insights on a potential “new standard of care” #MedSky #OncSky ow.ly/ssrv50XfpYg

🫁 Join us for our final session round-up from #ESMO2025 on Innovative Approaches in NSCLC: Beyond AGA, chaired by Lyudmila Bazhenova & May-Lucie Meyer Scroll through our thread for more on cutting-edge strategies like ADCs, bispecifics, PROTACs & DNA repair targeting #ESMO25 #OncSky #MedSky

Don’t miss expert insights on NF1 management from #EANO2025 over on our YouTube channel! We caught up with Said Farschtschi to discuss clinical challenges across both pediatric and adult populations, and the current treatment landscape #MedSky #NeuroSky ow.ly/84LP50XeLtW

🆕 What’s new in first-line and post-immunotherapy treatment for #NSCLC at #ESMO25? From chemotherapy combinations to bispecifics and biomarker-driven strategies, read through the thread below for a quick round-up of the expert insights you need to know! #MedSky #OncSky #LungCancer

That’s a wrap for this morning’s live session on biomarker-based personalisation in metastatic prostate cancer at #ESMO25! Keep an eye out for our thread on today’s mini oral session on metastatic NSCLC coming soon👀

“We may need to add TME biomarkers to build biologically based, therapeutically relevant classification signatures.” – Ana Aparicio at #ESMO25. Precision in aggressive variant #prostatecancer starts with deeper profiling🎯 #Oncology #OncSky #MedEd #MedSky #mPC

TP53, RB1, PTEN: understanding alterations in ARVPCm components is key 🔑 Ana Aparicio calls for better assessment tools to guide treatment decisions #ESMO25 #ProstateCancer #Oncology #OncSky #MedEd #MedSky #mPC

💭Ana Aparicio shares how AVPCm is linked to a distinct androgen plasticity phenotype and worse outcomes in advanced #prostatecancer, but its role as a disease classifier is still evolving #ESMO25 #Oncology #OncSky #MedEd #MedSky #mPC

🔎Ana Aparicio highlights the need to refine how we classify aggressive variant #prostatecancer: “AVPC criteria helps select patients for trials interrogating biology relevant to androgen-indifferent PC.” #ESMO25 #Oncology #OncSky #MedEd #MedSky #mPC

“PARPi may be approved in the mHSPC setting in the near future.” – @neerajagarwal.bsky.social at #ESMO25. Ongoing trials could expand the reach of precision therapy beyond mCRPC #ProstateCancer #Oncology #OncTwitter #MedEd #MedX #mPC #mHSPC

“Increased utilization of NGS testing is critical to optimize survival outcomes.” - @neerajagarwal.bsky.social at #ESMO25. Precision medicine in #prostatecancer starts with identifying who can benefit #Oncology #OncSky #MedEd #MedSky #mPC

PARPi combination therapy may be preferred over sequencing in mCRPC. @neerajagarwal.bsky.social suggests a shift in strategy could improve outcomes📈 #ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #mPC

💭@neerajagarwal.bsky.social shares insights on pairing targeted treatments. In mCRPC, BRCA1/2-altered tumors show maximum benefit from PARPi monotherapy. But combo therapy (PARPi + ARPI) may extend benefit to CDK12, PALB2, ATM, though trials weren’t powered for subset analysis #ESMO25 #MedSky

🧬~25–30% of advanced #prostatecancer patients have DNA repair pathway gene alterations, making them responsive to PARP inhibitors. @neerajagarwal.bsky.social highlights the growing role of HRR in treatment selection #ESMO25 #Oncology #OncSky #MedEd #MedSky #mPC

🔮Combining PET, blood, and clinical biomarkers may be the future of personalised care in mPC. Ken Herrmann outlines a multi-modal roadmap to smarter treatment #ESMO25 #Oncology #OncSky #MedEd #MedSky #ProstateCancer #mPC

PSMA PET scans are packed with potential, but making sense of all that data? That’s where automation steps in. Ken Herrmann shares insights on how PSMA-TTV could unlock new levels of precision in patient selection for radioligand therapy🔓 #ESMO25 #ProstateCancer #MedSky ##OncSky